Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design

David Kuter, Quentin A. Hill, Bruno Fattizzo, Deepthi Jayawardene, Ahmed Daak

Blood (2025) 146 (Supplement 1): 1123.

https://doi.org/10.1182/blood-2025-1123

Published: 2025

Journal Articles

Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

David Kuter, Nicola Cooper, Mattea Orsini, Jerome Msihid, Laurence Pollissard, Matias Cordoba, Ahmed Daak, Marek Wardecki, Lei Wang, Bruno Fattizzo

Blood (2025) 146 (Supplement 1): 1105.

https://doi.org/10.1182/blood-2025-1105

Published: 2025

Journal Articles

Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study

Alessandro Lucchesi, Nicola Cooper, Bruno Fattizzo, Lei Wang, Eric Boitier, Cintia C. Palu, Dimitri Carene, Vincent Mikol, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 2881.

https://doi.org/10.1182/blood-2025-2881

Published: 2025

Journal Articles

Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial

Blood (2025) 146 (Supplement 1): 4981.

https://doi.org/10.1182/blood-2025-4981

Published: 2025

Journal Articles

Early multi-immune modulation with rilzabrutinib in patients with primary ITP after first-line treatment failure: A phase 3b study (LUNA 4)

David Kuter, Waleed Ghanima, Nicola Cooper, Marie Luise Hütter-Krönke, Guillaume Moulis, Francesco Zaja, Maria Cristina Pascual Izquierdo, Howard Liebman, Sandhya Panch, Hisashi Kato, Matias Cordoba, Ahmed Daak, Maria Belen Rodriguez

Blood (2025) 146 (Supplement 1): 4827.

https://doi.org/10.1182/blood-2025-4827

Published: 2025

Journal Articles

Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy

Philip Choi, Charlotte Bradbury, Tomas Jose Gonzalez-Lopez, Muhlis Cem Ar, Karolin Trautmann-Grill, Mathias Rummel, Alessandra Borchiellini, Nicola Cooper, Fernando Chuliber, Rushad Patell, Blanca Sanchez, Patrick Urban, Alex Allepuz, Fabienne Le Gac, Renxin Lin, David Kuter

Blood (2025) 146 (Supplement 1): 844.

https://doi.org/10.1182/blood-2025-844

Published: 2025

Journal Articles

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Bruno Fattizzo, Henrik Frederiksen, Alessandro Lucchesi, Bing Han, Catherine Broome, Nicola Cooper, Joan Cid, Frederick Chen, Amitabha Mazumder, Míriam Vara Pampliega, Deepthi Jayawardene, Heidi Krenz, Jing Zhao, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 4655.

https://doi.org/10.1182/blood-2025-4655

Published: 2025

Journal Articles

Characterization of platelet autoantibody prevalence, serology, and predictive value for progression to immune thrombocytopenia in patients with persistent isolated mild thrombocytopenia (PIMT)

Ellen Zhang, Rebecca Leaf, Debbie Jiang, Katayoon Goodarzi, David Kuter, Hanny Al-Samkari

Blood (2025) 146 (Supplement 1): 1266.

https://doi.org/10.1182/blood-2025-1266

Published: 2025

Journal Articles

Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent/chronic immune thrombocytopenia in the long-term extension period of the Phase 3 LUNA3 study

David Kuter, Lei Zhang, Waleed Ghanima, Yoshitaka Miyakawa, Yu Hu, David Gomez-Almaguer, Matias Cordoba, Marek Wardecki, Larissa Mege, Meredith Foster, Ahmed Daak, Howard Liebman

Blood (2025) 146 (Supplement 1): 1260.

https://doi.org/10.1182/blood-2025-1260

Published: 2025

Journal Articles

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia

David Kuter, Chen Yunfei, Nicola Cooper, Waleed Ghanima, Hisashi Kato, Yoshiaki Tomiyama, Raymond Wong, Renchi Yang, Cheryl Li, Emily Skelton, Scarlett Wang, Donald Yee, Parth Patwari

Blood (2025) 146 (Supplement 1): 3049.

https://doi.org/10.1182/blood-2025-3049

Published: 2025

Journal Articles

Reproductive health in patients with primary immune thrombocytopenia (ITP) receiving rilzabrutinib: A subgroup analysis from the Phase 3 LUNA3 multicenter study

Michele Lambert, Nicola Cooper, Maria Cristina Pascual Izquierdo, Elisa Lucchini, Sylvain Audia, Huafang Wang, Yoshitaka Miyakawa, Meredith Foster, Maria Belen Rodriguez, Ahmed Daak, David Kuter

Blood (2025) 146 (Supplement 1): 3027.

https://doi.org/10.1182/blood-2025-3027

Published: 2025

Journal Articles

Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry

Ravi Vij, Mark Fiala, David Cella, Brian Durie, David Kuter, Claudio Cerchione, Kamaraj Karunanithi, Jing Bo Li, Amanda Crosbie, Gabriela Hernandez-Rivera, Antoine Tinel, Thomas S. Marshall, Meghan Podolsky, Karthik Ramasamy

Blood (2025) 146 (Supplement 1): 6345.

https://doi.org/10.1182/blood-2025-6345

Published: 2025

Journal Articles

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

Gordon Cook, MD PhD, David Cella, PhD, Brian Durie, MD, Hartmut Goldschmidt, MD, David Kuter, MD DPhil, Philippe Moreau, Ravi Vij, MD MBBS, Catherine Davis, Abderrahim Oukessou, Teresa Zyczynski, PharmD, MPH, MBA, BSPharm, Sergey Popov, Antonio Palumbo, MD

Blood (2015) 126 (23): 2093.

https://doi.org/10.1182/blood.V126.23.2093.2093

Published: 2015

Journal Articles

Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis

Annemarie E. Fogerty, MD, David Kuter, MD, DPhil, Jean M. Connors, MD

Blood (2008) 112 (11): 5251.

https://doi.org/10.1182/blood.V112.11.5251.5251

Published: 2008

Journal Articles

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

David Kuter, James Bussel, James George, Louis Aledort, Alan Lichtin, Roger Lyons, Jorge Nieva, Jeffrey Wasser, Emanuelle Bourgeois, Mies Kappers-Klunne, Francois Lefrere, Martin Schipperus, Reggie Kelly, Jenny Christal, Matthew Guo, Janet Nichol

Blood (2006) 108 (11): 476.

https://doi.org/10.1182/blood.V108.11.476.476

Published: 2006

Journal Articles

Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.

Ghulam Mufti, Adam Bagg, Robert Hasserjian, Barbara Bain, David Kuter, Lyndah Dreiling, Janet Nichol

Blood (2006) 108 (11): 3982.

https://doi.org/10.1182/blood.V108.11.3982.3982

Published: 2006

Journal Articles

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

David Kuter, MD, DPhil, James B. Bussel, MD, Louis M. Aledort, MD, James George, MD, Roger M. Lyons, MD, George T. Conklin, MD, Alan E. Lichtin, MD, Jorge Nieva, MD, Reggie Kelly, BA, Chien-Feng Chen, PhD, Janet L. Nichol, MS

Blood (2004) 104 (11): 511.

https://doi.org/10.1182/blood.V104.11.511.511

Published: 2004

Journal Articles

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

Blood (2004) 104 (11): 336.

https://doi.org/10.1182/blood.V104.11.336.336

Published: 2004

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Phase 3 Study to evaluate the efficacy and safety of rilzabrutinib in primary warm autoimmune hemolytic anemia (wAIHA): LUMINA 3 Study design

Fatigue, hemoglobin, and inflammatory markers in warm autoimmune hemolytic anemia: Analysis from a phase 2b trial of rilzabrutinib (LUMINA2)

Impact of rilzabrutinib on gene-expression of inflammatory factors in patients with warm autoimmune hemolytic anemia who participated in the Phase 2B lumina 2 study

Oral iptacopan monotherapy demonstrates clinically meaningful hemoglobin increases in patients with paroxysmal nocturnal hemoglobinuria with baseline hemoglobin levels 10 to <12 g/dl on anti-C5 therapy: Subgroup analysis of the appulse-pnh Phase 3b trial

Early multi-immune modulation with rilzabrutinib in patients with primary ITP after first-line treatment failure: A phase 3b study (LUNA 4)

Secondary analysis results from VAYHIT3, a phase 2 study of ianalumab in patients with primary immune thrombocytopenia previously treated with at least two lines of therapy

Long-term efficacy and safety of rilzabrutinib, an oral bruton tyrosine kinase (BTK) inhibitor in patients with warm autoimmune hemolytic anemia (wAIHA) in the LUMINA Phase 2b part B study: A 74-week follow-up

Characterization of platelet autoantibody prevalence, serology, and predictive value for progression to immune thrombocytopenia in patients with persistent isolated mild thrombocytopenia (PIMT)

Reduction in corticosteroid use with rilzabrutinib and sustained response in adults with persistent/chronic immune thrombocytopenia in the long-term extension period of the Phase 3 LUNA3 study

Trial in progress: Study design of a randomized, phase 3 trial evaluating the efficacy and safety of mezagitamab (TAK-079) compared with placebo in adults with chronic primary immune thrombocytopenia

Reproductive health in patients with primary immune thrombocytopenia (ITP) receiving rilzabrutinib: A subgroup analysis from the Phase 3 LUNA3 multicenter study

Reasons for treatment discontinuation in multiple myeloma: Insights from the PREAMBLE registry

An Ongoing Multinational Observational Study in Multiple Myeloma (PREAMBLE): Preliminary Report on Patient Survival

Gestational Platelet Trends and Outcomes in Women with Myeloproliferative Disorders Characterized by Thrombocytosis

Long-Term Dosing of AMG 531 in Thrombocytopenic Patients with Immune Thrombocytopenic Purpura: 48-Week Update.

Bone Marrow Reticulin in Patients with Immune Thrombocytopenic Purpura.

A Phase 2 Placebo Controlled Study Evaluating the Platelet Response and Safety of Weekly Dosing with a Novel Thrombopoietic Protein (AMG531) in Thrombocytopenic Adult Patients (pts) with Immune Thrombocytopenic Purpura (ITP).

Phase II Trial of Single Agent Bortezomib (VELCADE®) in Patients with Previously Untreated Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only